NDA 050819 · Bausch
Acanya
Benzoyl Peroxide, Clindamycin Phosphate · Topical
Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Oct 23, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
162
44 Phase 3, 7 recruiting
FAERS reports
309
79 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 15, 2025.
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Clindamycin Phosphate and Benzoyl Peroxide Gel is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. ( 1 )
Mechanism: Clindamycin: Clindamycin is a lincosamide antibacterial [see Microbiology (12.4) ] . Benzoyl Peroxide: Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 24, 2014 Supplement 12 · Efficacy LabelReviewLetter
- Oct 23, 2008 Original approval · Type 5 - New Formulation or New Manufacturer ReviewSummary ReviewLetter
2 products under this application
- ACANYA · BENZOYL PEROXIDE 2.5%; CLINDAMYCIN PHOSPHATE EQ 1.2% BASE · GEL, TOPICAL · Prescription · TE AB
- ONEXTON · BENZOYL PEROXIDE 3.75%; CLINDAMYCIN PHOSPHATE EQ 1.2% BASE · GEL, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Benzoyl Peroxide" as an intervention, any sponsor and status, largest first.
- Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne VulgarisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01742637 · 2,008 participants · Start Oct 2012 · Primary completion Feb 2014
Drug: Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%; Epiduo® Gel and 1 more · For: Acne Vulgaris
- A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT00421993 · 1,670 participants · Start Oct 2006 · Primary completion Oct 2007
Drug: Adapalene/Benzoyl Peroxide; Adapalene and 2 more · For: Acne Vulgaris
Sites: Huntsville, Alabama; Little Rock, Arkansas; Fresno, California · 62 sites in all
- Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT00422240 · 1,668 participants · Start Jun 27, 2006 · Primary completion Jul 12, 2007
Drug: Adapalene/Benzoyl Peroxide; Adapalene Gel, 0.1% and 2 more · For: Acne Vulgaris
Sites: San Antonio, Texas
- Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical GelsPivotal-lookingCompleted
Padagis LLCIndustry
NCT01138514 · 1,555 participants · Start Oct 2009 · Primary completion Oct 2010
Drug: Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo); Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin) and 1 more · For: Acne Vulgaris
- A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne VulgarisPivotal-lookingCompleted
Dow Pharmaceutical SciencesIndustry
NCT00664248 · 1,414 participants · Start Oct 2006 · Primary completion Aug 2007
Drug: IDP-110; Clindamycin and 2 more · For: Acne Vulgaris
Sites: Birmingham, Alabama; Huntsville, Alabama; Little Rock, Arkansas · 35 sites in all
- A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne VulgarisPivotal-lookingCompleted
Dow Pharmaceutical SciencesIndustry
NCT00663286 · 1,399 participants · Start Oct 2006 · Primary completion Aug 2007
Drug: IDP-110; Clindamycin and 2 more · For: Acne Vulgaris
Sites: Hot Springs, Arkansas; New Haven, Connecticut; Hockessin, Delaware · 33 sites in all
- Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With AcnePivotal-lookingCompleted
Stiefel, a GSK CompanyIndustry
NCT00776919 · 1,315 participants · Start Oct 2008 · Primary completion Sep 2009
Drug: clindamycin / benzoyl peroxide gel; clindamycin gel and 2 more · For: Acne Vulgaris
Sites: San Diego, California; Santa Monica, California; Denver, Colorado · 24 sites in all
- Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne VulgarisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT01769235 · 1,215 participants · Start Nov 2012 · Primary completion Sep 2013
Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%; Acanya® Gel, 1.2%/2.5% and 1 more · For: Acne Vulgaris
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective35
- erythema26
- acne25
- pruritus25
- rash22
- dry skin18
- expired product administered16
- nausea12
- skin discolouration12
- burning sensation11
- diarrhoea11
- dizziness11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 6 |
| 2014 | 12 |
| 2015 | 55 |
| 2016 | 69 |
| 2017 | 51 |
| 2018 | 32 |
| 2019 | 21 |
| 2020 | 21 |
| 2021 | 5 |
| 2022 | 8 |
| 2023 | 11 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 9 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Acanya (Clindamycin Phos/Benzoyl Perox)
2024 spending
$6K
Beneficiaries
n/a
12 claims
Per beneficiary
n/a
$9.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $33,712 |
| 2021 | $15,965 |
| 2022 | $9,929 |
| 2023 | $14,030 |
| 2024 | $5,561 |
Part D: Onexton (Clindamycin Phos/Benzoyl Perox)
2024 spending
$63K
Beneficiaries
38
89 claims
Per beneficiary
$1,656
$13.83 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $274,972 |
| 2021 | $348,412 |
| 2022 | $405,573 |
| 2023 | $414,937 |
| 2024 | $62,934 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Acne and the cutaneous microbiome: A systematic review of mechanisms and implications for treatments.
Podwojniak A, Tan IJ, Sauer J, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review
- A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris.
Mavranezouli I, Daly CH, Welton NJ, et al. · Br J Dermatol 2022 · Systematic Review, Network Meta-Analysis
- Topical Retinoids in Acne Vulgaris: A Systematic Review.
Kolli SS, Pecone D, Pona A, et al. · Am J Clin Dermatol 2019 · Systematic Review
- Systematic review of antibiotic resistance in acne: an increasing topical and oral threat.
Walsh TR, Efthimiou J, Dréno B · Lancet Infect Dis 2016 · Systematic Review
- Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review.
Gray NA, Tod B, Rohwer A, et al. · J Eur Acad Dermatol Venereol 2022 · Systematic Review
Sponsor: Bausch · Also marketed as Onexton
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.